Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372628 · ClinicalTrials.gov registry record · Phase 2
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 452
- Enrollment target
NCT04372628: Completed Phase 2 study, sponsored by Vanderbilt University Medical Center.
NCT04372628 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 452 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (240% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04372628, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 452 participants
- Enrollment target
Study Summary
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19
Primary Outcome
Improvement of clinical condition of the participant defined by the Modified COVID Ordinal Outcomes Scale (Modified from the COVID-19 WHO ordinal Outcomes score to fit the outpatient setting). This scale reflects a range of participants from dead to not hospitalized and with no limitations to activities of daily living. A score of 1 is "death", 2 is "Hospitalized on mechanical ventilation or extracorporeal membrane oxygenator (ECMO)", 3 is "Hospitalized on supplemental oxygen", 4 is "Hospitalize
Interventions
- OTHER Placebo
- DRUG Lopinavir/Ritonavir 400 mg/100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2022-01-18 |
| Phase | Phase 2 |
What the finished NCT04372628 record still lists
NCT04372628 is an interventional study that assigns participants to a tested intervention. The registered 452 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (240% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04372628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04372628 about?
NCT04372628 is a clinical study titled "Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19". Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19
What is the current status of trial NCT04372628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 452 participants. The study started on 2020-06-01. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04372628?
The interventions under investigation include: Placebo (OTHER), Lopinavir/Ritonavir 400 mg/100 mg (DRUG).
Who is sponsoring clinical trial NCT04372628?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04372628's enrollment target sits among peer trials
452 87th of 2000 higher than 1,914 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI